Assessment of Knowledge, Attitudes, and Practices Regarding Dengue among Physicians: A Web-Based Cross-Sectional Survey

Abstract

Dengue fever is one of the most important viral infections transmitted by Aedes mosquitoes and a major cause of morbidity and mortality globally. Accurate identification of cases and treatment of dengue patients at the early stages can reduce medical complications and dengue mortality rate. This survey aims to determine the knowledge, attitude, and practices (KAP) among physicians in dengue diagnosis and treatment. This study was conducted among physicians in Turkey as one nonendemic country and Bangladesh, India, and Malaysia as three dengue-endemic countries. The dosing frequencies, maximum doses, and contraindications in dengue fever were examined. The results found that physicians from Bangladesh, India, and Malaysia have higher KAP scores in dengue diagnosis and treatment compared to physicians in Turkey. This may be due to a lack of physician’s exposure to a dengue patient as Turkey is considered a nonendemic country. This assessment may help establish a guideline for intervention strategies among physicians to have successful treatment outcomes and reduce dengue mortality.

Human monkeypox and preparedness of Bangladesh: A knowledge and attitude assessment study among medical doctors

“…In a similar study, general practitioners in Indonesia knew relatively little about the emerging infection known as monkeypox [13] , [14] . In contrast, regarding endemic diseases in Bangladesh, the level of knowledge is rather high; most doctors are well-versed in diseases such as "dengue," which are transmitted by Aedes aegypti [18] . It should not come as a surprise that participants in general lack awareness about monkeypox since it is a re-emerging infectious disease, and instances of it have never been documented in Bangladesh.…”

Knowledge and Perceptions about Diagnosis, Clinical Management, and Prevention of Dengue Fever among Physicians during the 2023 outbreak: A Cross-Sectional Study in Peru

“…In Tanzania, Saringe et al (Saringe et al, 2019) found that 74.1% of healthcare workers possessed good dengue knowledge, with a mean score of 43.6 (considered good if ≥ 40). Additionally, a multi-country study revealed that Bangladesh, India, and Malaysia had the highest dengue knowledge scores (16.9, 18.03, and 18.46, respectively), while Turkey scored lower (11.7) (Koonisetty et al, 2021). These studies suggest that the good knowledge could be due to the constant dengue cases presented in those areas, a situation similar to Peru.…”

“…al., 2021;Koonisetty et al, 2021;Tomashek et al, 2014). However, this study divided respondents according to macroregions within the same country, and despite the fact that the Eastern macroregion tends to have the highest number of cases and is considered a dengue endemic area (Ministerio de Salud del Perú, 2023g), in the multivariable analysis, living in this macroregion was negatively associated with obtaining a score ≥ 70%.…”

Insight parameter drug design for human beta-tryptase inhibition integrated molecular docking, QSAR, molecular dynamics simulation, and pharmacophore modelling studies of alpha-keto-[1,2,4]-oxadiazoles

“…Besides, the WHO Strategic Advisory Panel has recommended the use of Dengvaxia® for dengue-seropositive patients only because it has been found to increase the risk of severe dengue in seronegative individuals [5], [6]. To date, dengue treatment has relied on the management of clinical signs and symptoms, including the prescription of non-steroidal anti-inflammatory agents (NSAIDs), clinical parameters tracking, and fluid management to stabilise hemodynamic status [7]. Currently, there is still no specific treatment for dengue [2], [7], [8].…”

“…To date, dengue treatment has relied on the management of clinical signs and symptoms, including the prescription of non-steroidal anti-inflammatory agents (NSAIDs), clinical parameters tracking, and fluid management to stabilise hemodynamic status [7]. Currently, there is still no specific treatment for dengue [2], [7], [8]. Although some drugs such as chloroquine, balapiravir, and lovastatin are being tested in human clinical trials to treat dengue at different stages of development, these drugs have not been approved yet for use against dengue [9], [10].…”